Your browser doesn't support javascript.
loading
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.
Antony, Paul A; Paulos, Chrystal M; Ahmadzadeh, Mojgan; Akpinarli, Akgül; Palmer, Douglas C; Sato, Noriko; Kaiser, Andrew; Hinrichs, Christian S; Heinrichs, Christian; Klebanoff, Christopher A; Tagaya, Yutaka; Restifo, Nicholas P.
Afiliação
  • Antony PA; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. paul_antony@mac.com
J Immunol ; 176(9): 5255-66, 2006 May 01.
Article em En | MEDLINE | ID: mdl-16621991
ABSTRACT
IL-2 is a critical T cell growth factor in vitro, but predominantly mediates tolerance in vivo. IL-2 is mainly produced by CD4(+) Th cells, but the role of Th cell-derived IL-2 in vivo is controversial. We demonstrate that during immunity to a tumor/self-Ag, the predominant role of Th cell-derived IL-2 was to maintain IL-2Ralpha (CD25) on CD4(+) T regulatory cells (T(reg)), which resulted in their maintenance of the T(reg) cell lineage factor, Forkhead/winged helix transcription factor (Foxp3), and tolerance. However, in the absence of T(reg) cells, Th cell-derived IL-2 maintained effector T cells and caused autoimmunity. IL-2R signaling was indispensable for T(reg) cell homeostasis and efficient suppressor function in vivo, but, surprisingly, was not required for their generation, because IL-2(-/-) and CD25(-/-) mice both contained Foxp3(+) T cells in the periphery. IL-2R signaling was also important for CD8(+) T cell immunity, because CD25(-/-) tumor-reactive CD8(+) T cells failed to affect established tumors. Conversely, IL-2R signaling was not required for Th cell function. Lastly, administration of anti-IL-2 plus exogenous IL-15 to tumor-bearing mice enhanced the adoptive immunotherapy of cancer. Therefore, Th cell-derived IL-2 paradoxically controls both tolerance and immunity to a tumor/self-Ag in vivo.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Tolerância Imunológica Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunol Ano de publicação: 2006 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Tolerância Imunológica Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunol Ano de publicação: 2006 Tipo de documento: Article País de afiliação: Estados Unidos